Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Therapeutics. Pharmacology
RM1-950
Public aspects of medicine
RA1-1270
Acceso en línea:https://doaj.org/article/86aa2e97af2349d6999630760b8de569
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares